Successfully treating reduced motivation, or avolition, in patients with schizophrenia has a positive effect on other negative symptoms, according to a study published online in Schizophrenia Bulletin.
Long-term use of antipsychotics by patients with schizophrenia does not increase the risk of hospitalization for comorbid conditions—and is actually associated with substantially decreased mortality, according to a study in World Psychiatry.
Cognitive aging appears to occur more rapidly in people with psychotic disorders, compared with peers without such disorders, according to a study that followed 445 people for 2 decades after their first psychotic disorder hospitalization.
Abnormally high levels of a hydrogen sulfide-producing enzyme detectable in human hair may act as a biomarker for patients with a particular subtype of schizophrenia, according to a study published online in EMBO Molecular Medicine.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.